home / stock / pmcb / pmcb news

PMCB News and Press, PharmaCyte Biotech Inc. From 06/02/22

Stock Information
Company Name: PharmaCyte Biotech Inc.
Stock Symbol: PMCB
Market: OTC
Website: pharmacyte.com
Menu
PMCB PMCB Quote PMCB Short PMCB News PMCB Articles PMCB Message Board
Get PMCB Alerts

News, Short Squeeze, Breakout and More Instantly...
PMCB - PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Board of Director...
PMCB - PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has initiated the first in a series of studies to ...

PMCB - Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors PR Newswire Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash ...

PMCB - PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the management team will be attending the 15th Intern...
PMCB - PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the empty capsule material that comprises its pancrea...

PMCB - PharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical hold

PharmaCyte Biotech (NASDAQ:PMCB) has decided to accelerate preparations for the start of its phase 2b trial in locally advanced, inoperable pancreatic (LAPC) using its CypCaps product, even as clinical hold by the FDA on the trial remains. PharmaCyte's CEO Kenneth Waggoner, said of ...

PMCB - PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that PharmaCyte has decided to accelerate preparations for...
PMCB - PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today the appointment of Dr. Matthias Löhr to PharmaCyt...

PMCB - PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed a 24-month product ...

PMCB - PharmaCyte Biotech reports Q3 results

PharmaCyte Biotech press release (NASDAQ:PMCB): Q3 cash on hand of approximately $87M as of January 31, 2022. For further details see: PharmaCyte Biotech reports Q3 results

Previous 10 Next 10